BIOA
BioAge Labs, Inc.
Biotechnology
Market Cap$641M
5Y Perf.-14.3%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
BIOA vs RYTM
Revenue, margins, valuation, and 5-year total return — side by side.
RYTM
Rhythm Pharmaceuticals, Inc.
Biotechnology
Market Cap$6.59B
5Y Perf.+83.7%
BIOA vs RYTM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BIOA | RYTM |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $641M | $6.59B |
| Revenue (TTM) | $9M | $217M |
| Net Income (TTM) | $-81M | $-204M |
| Gross Margin | 99.2% | 89.4% |
| Operating Margin | -10.3% | -90.9% |
| Total Debt | $6M | $246M |
| Cash & Equiv. | $189M | $54M |
BIOA vs RYTM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BIOA
RYTM
| Stock | Sep 24 | May 26 | Return |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | 100 | 85.7 | -14.3% |
| Rhythm Pharmaceutic… (RYTM) | 100 | 183.7 | +83.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BIOA vs RYTM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: RYTM leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. BioAge Labs, Inc. is the stronger pick specifically for recent price momentum and sentiment and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
BIOA
BioAge Labs, Inc.
The Growth Play
BIOA is the clearest fit if your priority is growth exposure and sleep-well-at-night.
- EPS growth 66.2%
- Lower volatility, beta 1.41, Low D/E 2.0%, current ratio 14.24x
- +338.9% vs RYTM's +48.9%
Best for: growth exposure and sleep-well-at-night
RYTM
Rhythm Pharmaceuticals, Inc.
The Income Pick
RYTM carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 1 yrs, beta 1.04
- 220.8% 10Y total return vs BIOA's -2.7%
- Beta 1.04, current ratio 4.41x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RYTM | 45.8% revenue growth vs BIOA's -13.3% |
| Quality / Margins | RYTM | -93.8% margin vs BIOA's -9.0% |
| Stability / Safety | RYTM | Beta 1.04 vs BIOA's 1.41 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | BIOA | +338.9% vs RYTM's +48.9% |
| Efficiency (ROA) | BIOA | -25.5% ROA vs RYTM's -45.2%, ROIC -210.2% vs -70.1% |
BIOA vs RYTM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
BIOA vs RYTM — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRYTMLAGGINGBIOA
BIOABioAge Labs, Inc.
1leads
RYTMRhythm Pharmaceutical…
4leads
6 Total Categories
CATEGORYLEADERvs BIOAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
RYTM3/5
Valuation MetricsMultiples, price ratios, and targets
RYTM2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
BIOA6/8
Total Returns1Y, 3Y, 5Y total returns with dividends
RYTM4/6
Risk & VolatilityBeta, volatility, and downside exposure
RYTM2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
RYTM leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
RYTM is the larger business by revenue, generating $217M annually — 24.1x BIOA's $9M. Profitability is closely matched — net margins range from -93.8% (RYTM) to -9.0% (BIOA).
| Metric | BIOABioAge Labs, Inc. | RYTMRhythm Pharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $9M | $217M |
| EBITDAEarnings before interest/tax | -$93M | -$196M |
| Net IncomeAfter-tax profit | -$81M | -$204M |
| Free Cash FlowCash after capex | -$82M | -$76M |
| Gross MarginGross profit ÷ Revenue | +99.2% | +89.4% |
| Operating MarginEBIT ÷ Revenue | -10.3% | -90.9% |
| Net MarginNet income ÷ Revenue | -9.0% | -93.8% |
| FCF MarginFCF ÷ Revenue | -9.2% | -35.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +83.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +63.5% | -2.5% |
RYTM leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
RYTM leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | BIOABioAge Labs, Inc. | RYTMRhythm Pharmaceut… |
|---|---|---|
| Market CapShares × price | $641M | $6.6B |
| Enterprise ValueMkt cap + debt − cash | $458M | $6.8B |
| Trailing P/EPrice ÷ TTM EPS | -7.96x | -30.94x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 71.28x | 34.75x |
| Price / BookPrice ÷ Book value/share | 2.35x | 44.97x |
| Price / FCFMarket cap ÷ FCF | — | — |
RYTM leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
BIOA leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
BIOA delivers a -27.9% return on equity — every $100 of shareholder capital generates $-28 in annual profit, vs $-2 for RYTM. BIOA carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to RYTM's 1.77x.
| Metric | BIOABioAge Labs, Inc. | RYTMRhythm Pharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | -27.9% | -2.0% |
| ROA (TTM)Return on assets | -25.5% | -45.2% |
| ROICReturn on invested capital | -2.1% | -70.1% |
| ROCEReturn on capital employed | -30.7% | -58.9% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 |
| Debt / EquityFinancial leverage | 0.02x | 1.77x |
| Net DebtTotal debt minus cash | -$183M | $192M |
| Cash & Equiv.Liquid assets | $189M | $54M |
| Total DebtShort + long-term debt | $6M | $246M |
| Interest CoverageEBIT ÷ Interest expense | -118.34x | -12.41x |
BIOA leads this category, winning 6 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
RYTM leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RYTM five years ago would be worth $43,504 today (with dividends reinvested), compared to $9,732 for BIOA. Over the past 12 months, BIOA leads with a +338.9% total return vs RYTM's +48.9%. The 3-year compound annual growth rate (CAGR) favors RYTM at 79.4% vs BIOA's -0.9% — a key indicator of consistent wealth creation.
| Metric | BIOABioAge Labs, Inc. | RYTMRhythm Pharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | +38.9% | -8.4% |
| 1-Year ReturnPast 12 months | +338.9% | +48.9% |
| 3-Year ReturnCumulative with dividends | -2.7% | +477.3% |
| 5-Year ReturnCumulative with dividends | -2.7% | +335.0% |
| 10-Year ReturnCumulative with dividends | -2.7% | +220.8% |
| CAGR (3Y)Annualised 3-year return | -0.9% | +79.4% |
RYTM leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
RYTM leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
RYTM is the less volatile stock with a 1.04 beta — it tends to amplify market swings less than BIOA's 1.41 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RYTM currently trades 78.7% from its 52-week high vs BIOA's 74.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BIOABioAge Labs, Inc. | RYTMRhythm Pharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.41x | 1.04x |
| 52-Week HighHighest price in past year | $24.00 | $122.20 |
| 52-Week LowLowest price in past year | $3.67 | $55.31 |
| % of 52W HighCurrent price vs 52-week peak | +74.3% | +78.7% |
| RSI (14)Momentum oscillator 0–100 | 55.2 | 67.9 |
| Avg Volume (50D)Average daily shares traded | 464K | 853K |
RYTM leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates BIOA as "Buy" and RYTM as "Buy". Consensus price targets imply 152.5% upside for BIOA (target: $45) vs 45.5% for RYTM (target: $140).
| Metric | BIOABioAge Labs, Inc. | RYTMRhythm Pharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $45.00 | $140.00 |
| # AnalystsCovering analysts | 3 | 20 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
RYTM leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). BIOA leads in 1 (Profitability & Efficiency).
Best OverallRhythm Pharmaceuticals, Inc. (RYTM)Leads 4 of 6 categories
Loading custom metrics...
BIOA vs RYTM: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is BIOA or RYTM a better buy right now?
Analysts rate BioAge Labs, Inc.
(BIOA) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BIOA or RYTM?
Over the past 5 years, Rhythm Pharmaceuticals, Inc.
(RYTM) delivered a total return of +335. 0%, compared to -2. 7% for BioAge Labs, Inc. (BIOA). Over 10 years, the gap is even starker: RYTM returned +220. 8% versus BIOA's -2. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BIOA or RYTM?
By beta (market sensitivity over 5 years), Rhythm Pharmaceuticals, Inc.
(RYTM) is the lower-risk stock at 1. 04β versus BioAge Labs, Inc. 's 1. 41β — meaning BIOA is approximately 35% more volatile than RYTM relative to the S&P 500. On balance sheet safety, BioAge Labs, Inc. (BIOA) carries a lower debt/equity ratio of 2% versus 177% for Rhythm Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — BIOA or RYTM?
On earnings-per-share growth, the picture is similar: BioAge Labs, Inc.
grew EPS 66. 2% year-over-year, compared to 28. 3% for Rhythm Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — BIOA or RYTM?
Rhythm Pharmaceuticals, Inc.
(RYTM) is the more profitable company, earning -103. 6% net margin versus -896. 1% for BioAge Labs, Inc. — meaning it keeps -103. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RYTM leads at -101. 2% versus -1031. 5% for BIOA. At the gross margin level — before operating expenses — BIOA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — BIOA or RYTM?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is BIOA or RYTM better for a retirement portfolio?
For long-horizon retirement investors, Rhythm Pharmaceuticals, Inc.
(RYTM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 04), +220. 8% 10Y return). Both have compounded well over 10 years (RYTM: +220. 8%, BIOA: -2. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between BIOA and RYTM?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: BIOA is a small-cap quality compounder stock; RYTM is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.